Telitacicept not checked
RemeGen · RC18 · RC18 240 mg
FollowEvery change as it happens, and a Monday email
Trials
3 active
16 in total
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “The dosage is administered based on the subject's age and baseline body weight.”In the company’s words, NCT07249632 on ClinicalTrials.gov
- Tested for
- Primary IgA Nephropathy, Myasthenia Gravis, Ocular, CTD-ILD
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).”In the company’s words, NCT05799287 on ClinicalTrials.gov
- Other names
- RC18 · RC18 240 mg · RC18 160 mg · RC 18 80 mg · MTX=Methotrexate · Standard therapy
Other drugs for Primary IgA Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up2
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jun 2026 | A Study of Telitacicept for IgA Nephropathy (TELIGAN) | |
| Phase 3Recruiting | 31 Dec 2026 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | |
| Phase 3Not yet recruiting | 31 May 2029 | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease | |
| Phase 3Completed | 24 Apr 2022 | Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) | |
| Phase 3Completed | 19 Nov 2022 | A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. | |
| Phase 3Completed | 29 Oct 2024 | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome | |
| Phase 3Completed | 26 Nov 2024 | Study of Telitacicept in Generalized Myasthenia Gravis | |
| Phase 3Terminated | 3 Apr 2026 | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders | |
| Phase 2Completed | 20 May 2021 | A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy | |
| Phase 2Completed | 23 Jun 2021 | A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome | |
| Phase 2Completed | 14 Jan 2022 | A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | |
| Phase 2Terminated | 9 Nov 2023 | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy | |
| Phase 2Unknown | Dec 2025 | A Study of Telitacicept in Lupus Nephritis | |
| Phase 2Terminated | 3 Apr 2026 | RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial | |
| Phase 1Completed | 25 Oct 2023 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | |
| Phase 1Completed | 14 Nov 2025 | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026